Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) by 390.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,684 shares of the company’s stock after acquiring an additional 33,185 shares during the quarter. Barclays PLC owned approximately 0.14% of Dianthus Therapeutics worth $1,141,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in DNTH. Bank of New York Mellon Corp lifted its stake in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after purchasing an additional 72,509 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $832,000. American Century Companies Inc. lifted its stake in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after acquiring an additional 8,473 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $265,000. Finally, Great Point Partners LLC grew its position in Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after acquiring an additional 132,929 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.
Dianthus Therapeutics Stock Performance
Shares of NASDAQ DNTH opened at $23.04 on Tuesday. The company’s 50 day moving average price is $24.48 and its 200-day moving average price is $26.61. Dianthus Therapeutics, Inc. has a 52-week low of $10.65 and a 52-week high of $33.77. The company has a market capitalization of $681.91 million, a P/E ratio of -9.22 and a beta of 1.74.
Analysts Set New Price Targets
Several equities analysts have commented on the company. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Oppenheimer raised their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and an average target price of $46.43.
Get Our Latest Research Report on DNTH
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Recommended Stories
- Five stocks we like better than Dianthus Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- The 3 Best Fintech Stocks to Buy Now
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Election Stocks: How Elections Affect the Stock Market
- Delta Can Fly to New Highs in 2025; Here’s Why
Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report).
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.